Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00813072 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Stomach Neoplasms
Esophageal Neoplasms

Interventions

DRUG: PEP02
DRUG: irinotecan
DRUG: docetaxel

Sponsor

PharmaEngine